This study is a randomized, prospective study, which will analyze the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention. The efficacy will include objective response rate, disease control rate, progression-free survival, and overall survival. The safety will include adverse events and quality of life.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
advanced central non-small cell lung cancer patients, untreated, tolerating bronchoscopy
You may not be if
contraindications to tracheoscopy, chemotherapy, and immunotherapy